Stein R1, Griffiths GL1, Cardillo T1, Blumenthal R1, Horak ID1, Goldenberg DM1.
J Clin Oncol. 2004 Jul 15;22(14_suppl):6535.6535 Background: CD74, a cell-surface-expressed epitope of the HLA class II-associated invariant chain [Ii], is a unique target for antibody-drug immunoconjugate therapy, being a transmembrane chaperone molecule that actively directs transport from the cell surface to an endosomal compartment. IMMU-110 is a drug immunoconjugate comprised of doxorubicin (dox) conjugated to the humanized anti-CD74 monoclonal antibody (MAb), hLL1, at 6-8 drug molecules per IgG molecule. Read More